Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

IL12 antibody (Interleukin 12) Primary Antibody

IL12 Reactivity: Human BR, ELISA, FACS, IP, WB Host: Mouse Monoclonal Ustekinumab unconjugated
Catalog No. ABIN6730996
$360.00
Plus shipping costs $45.00
100 μL
local_shipping Shipping to: United States
Delivery in 7 to 8 Business Days
  • Target
    IL12
    Antibody Type
    Recombinant Antibody
    Reactivity
    • 75
    • 31
    • 16
    • 8
    • 6
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Host
    • 44
    • 34
    • 31
    • 16
    • 2
    Mouse
    Clonality
    • 73
    • 50
    Monoclonal
    Conjugate
    • 55
    • 21
    • 7
    • 7
    • 6
    • 5
    • 4
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    This IL12 antibody is un-conjugated
    Application
    • 88
    • 71
    • 26
    • 22
    • 16
    • 15
    • 14
    • 11
    • 9
    • 7
    • 6
    • 5
    • 4
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB)
    Purpose
    Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23.
    Specificity
    "Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23."
    Characteristics
    "This is a therapeutic antibody derived from Stelara and designed for research purposes. Ustekinumab, the active ingredient of Stelara, is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23."
    Ustekinumab is a fully human IgG1κ monoclonal antibody that binds with specificity to the shared p40 protein subunit of human cytokines interleukin (IL)-12 and IL-23. Ustekinumab inhibits the bioactivity of human IL-12 and IL-23 by preventing p40 from binding to the IL-12R1 receptor protein expressed on the surface of immune cells. Ustekinumab cannot bind to IL-12 or IL-23 that is already bound to IL-12R1 cell surface receptors. Thus, ustekinumab is not likely to contribute to complement- or antibody-mediated cytotoxicity of cells with IL-12 and/or IL-23 receptors. IL-12 and IL-23 are heterodimeric cytokines secreted by activated antigen presenting cells, such as macrophages and dendritic cells, and both cytokines participate in immune functions; IL-12 stimulates natural killer (NK) cells and drives the differentiation of CD4+ T cells toward the T helper 1 (Th1) phenotype, IL- 23 induces the T helper 17 (Th17) pathway. However, abnormal regulation of IL 12 and IL 23 has been associated with immune mediated diseases, such as psoriasis, psoriatic arthritis and Crohn’s disease.
    By binding the shared p40 subunit of IL-12 and IL-23, ustekinumab may exert its clinical effects in psoriasis, psoriatic arthritis and Crohn’s disease through interruption of the Th1 and Th17 cytokine pathways, which are central to the pathology of these diseases.
    In patients with Crohn’s disease, treatment with ustekinumab resulted in a decrease in inflammatory markers including C-Reactive Protein (CRP) and fecal calprotectin during the induction phase, which were then maintained throughout the maintenance phase.
    Purification
    The commercial therapeutic mAb was diluted with sterile PBS to a final 1 mg/ml.  (original drug Stelara 90 was diluted 1:90)
    Sterility
    Sterile
    Clone
    Ustekinumab
  • Application Notes
    Optimal dilution for a specific application should be determined by user
    Comment

    Ustekinumab is a fully human IgG1κ monoclonal antibody to interleukin(IL)-12/23 produced in a murine myeloma cell line using recombinant DNA technology

    Protocol
    Research-relevant quantities are available as licence-free consumable as diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    The dilutant is sterile PBS pH 7.4. No preservatives added
    Preservative
    Without preservative
    Handling Advice
    open only under sterile conditions
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
    Expiry Date
    36 months
  • Target
    IL12
    Alternative Name
    IL-12 (IL12 Antibody Abstract)
    Synonyms
    CLMF, CLMF2, IL-12B, NKSF, NKSF2, p40, Il-12b, Il12p40, Il-12p40, Il12, IL-12p40, IL-12, LOC100217488, IL-12p35, Il-12a, Ll12a, p35, IL12p40, IL12B, IL-12 p35, interleukin 12B, interleukin 12A, interleukin 12b, interleukin 12a, Interleukin 12 level, IL12B, IL12A, Il12b, Il12a, IL12, il12a
    Background
    Synonyms: CLMF, CLMF2, IL-12B, NKSF, NKSF2, p40, Il-12b, Il12p40, Il-12p40, Il12, IL-12p40, LOC100217488, IL-12p35, Il-12a, Ll12a, p35, IL12p40, IL12B, IL-12 p35
    Molecular Weight
    37 kDa
    Gene ID
    3592
    UniProt
    P29459
    Pathways
    JAK-STAT Signaling, TLR Signaling, Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Activated T Cell Proliferation, Cancer Immune Checkpoints, Inflammasome
You are here:
help Support